Table 2A ASD risk associated with maternal antidepressant exposure during pregnancy

From: Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system

  ASD Controls ASD vs ASD-matched controls a
  1377 4022 Unadjusted Model 1 Model 2
Antidepressant exposure    OR (95% CI) OR (95% CI) OR (95% CI)
Time period
 Prepregnancy 6.6% 3.5% 1.98 (1.50–2.59)***   1.91 (1.41–2.58)***   1.62 (1.17–2.23)**  
 Preconception (conception - 30 days) 1.7% 1.0% 1.72 (1.02–2.84)*   1.89 (1.07–3.30)*   1.47 (0.81–2.61)  
 1st trimester 2.3% 1.3% 1.76 (1.11–2.74)*   1.84 (1.11–3.00)*   1.43 (0.85–2.38)  
 2nd trimester 2.0% 1.2% 1.76 (1.08–2.79)*   1.81 (1.07–3.00)*   1.34 (0.77–2.27)  
 3rd trimester 1.8% 1.1% 1.60 (0.96–2.59)   1.48 (0.85–2.50)   1.08 (0.61–1.88)  
 Pregnancy (preconception - delivery) 2.9% 2.0% 1.49 (1.01–2.18)*   1.45 (0.94–2.19)   1.10 (0.70–1.70)  
  1. Abbreviations: ADHD, attention-deficit hyperactivity disorder; ASD, Autism Spectrum Disorder; CI, confidence interval; OR, odds ratio.
  2. Unadjusted and adjusted risk of ASD compared with ASD-matched controls; Significance at P<0.05 (*), <0.01 (**), <0.001 (***). Model 1 is adjusted for gender, race, birth year, insurance type, maternal age and median income tertile. Model 2 is adjusted for variables in model 1 and past history of maternal depression.